Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zynex, Inc. (“Zynex” or “the Company”) (NASDAQ:ZYXI) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Zynex investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. ...

Core Viewpoint - Zynex, Inc. is under investigation for potential claims related to a class action complaint alleging that the company's board of directors breached their fiduciary duties by misleading investors about financial performance and operational practices [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint claims that Zynex's management engaged in practices that artificially inflated the company's stock price through false statements regarding financial performance and compliance with insurance reimbursement policies [2]. - It is alleged that Zynex operated a systemic "oversupplying scheme," shipping excessive quantities of supplies to patients and billing insurers significantly more than necessary [2]. Financial Impact and Regulatory Scrutiny - The extent of Zynex's misconduct was revealed on March 11, 2025, when the company announced a revenue shortfall due to slower payments from insurers, particularly Tricare, which accounted for 20-25% of its annual revenue [3]. - Following the announcement, Zynex's stock price fell by $3.59 per share, or 51.3%, closing at $3.41 per share, indicating a severe loss of shareholder value and highlighting the company's exposure to regulatory and financial risks [4].

Sustainable Energy Shift - Tesla is driving the shift to sustainable energy [1] - Tesla utilizes electric cars, solar power, and batteries [1] - The company aims to cut fossil fuel use and fight climate change [1]

Batteries are critical to smooth out the power fluctuations from AI training and grid voltage drops, as even a small change in power causes AI training to failJesse Peltan (@JessePeltan):You cannot train AGI without batteries.China knows this.Anybody who’s paying attention knows this.If we cannot make batteries — we lose. ...

Core Viewpoint - The article highlights the potential investment opportunity in O'Reilly Automotive, driven by favorable market trends and the company's strong financial performance, despite concerns over its current valuation [2][10]. Group 1: Market Trends - The average age of vehicles on the road in the U.S. has reached 12.8 years, increasing for eight consecutive years, which is expected to benefit O'Reilly Automotive as older vehicles require more maintenance [5]. - The macroeconomic environment, characterized by high interest rates on auto loans and rising material and labor costs, makes purchasing new vehicles less affordable, leading consumers to invest in repairs for their existing cars [8]. Group 2: Company Performance - O'Reilly Automotive reported a same-store sales increase of 2.9% in 2024, marking its 32nd consecutive year of growth, showcasing its resilience in various economic conditions [9]. - The company has effectively utilized its free cash flow for stock buybacks, reducing its outstanding share count by 24% over the past five years, which may enhance shareholder value [10]. Group 3: Valuation Concerns - Despite the positive growth and demand, O'Reilly's current price-to-earnings ratio stands at 32.8, which is 36% higher than its trailing 10-year average, raising concerns about its valuation [11].

Company Overview - O'Reilly Automotive has seen a remarkable stock performance, climbing 509% over the past decade and outperforming the S&P 500 index [3] - Since its IPO in April 1993, O'Reilly's stock has skyrocketed 56,350%, indicating strong business fundamentals and shareholder value [9] Stock Split Details - On March 13, O'Reilly's board approved a 15-for-1 stock split, which was implemented on June 10, reducing the share price from approximately $1,350 to $90 [6] - The stock split increased the number of outstanding shares by a factor of 15, making shares more accessible to investors [5][6] Business Model and Demand Stability - O'Reilly operates 6,416 stores, primarily selling aftermarket auto parts, which are in stable demand regardless of economic conditions [10] - The necessity of maintaining working automobiles supports consistent demand, as consumers tend to either drive more in good times or maintain existing vehicles during recessions [11] Financial Performance - O'Reilly generated $2 billion in free cash flow in 2024 and reported $455 million in Q1, with a history of using this cash for share buybacks [12] - The diluted outstanding share count has been reduced by 24% over the last five years, enhancing earnings per share [12] Valuation Considerations - O'Reilly's stock trades at a price-to-earnings ratio of 33.3, which is 38% higher than its trailing-10-year average, suggesting that the stock may be overvalued [13] - A recommendation is made for investors to consider waiting for a pullback before investing, although a dollar-cost averaging strategy could be viable for those bullish on the stock [13]

Core Viewpoint - A class-action lawsuit has been filed against Zynex, Inc. alleging that the company misled investors by inflating revenue through excessive and unnecessary shipments of medical supplies to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Tuncel v. Zynex, Inc., seeks to represent individuals and entities who purchased Zynex securities between March 13, 2023, and March 11, 2025, with a lead plaintiff deadline of May 19, 2025 [2][3]. - The complaint alleges that Zynex engaged in a scheme to inflate reported revenue by sending more products than medically necessary, which drew scrutiny from insurers like Tricare [3][4]. - Following a report in the medical journal STAT detailing Zynex's alleged oversupplying scheme, the company's stock price fell by over 5% [4]. Group 2: Financial Impact - Zynex disclosed a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [5]. - The announcement of the revenue shortfall led to a sharp decline in Zynex's share price, which plummeted by more than 51% [5]. - In Q1 2025, Zynex reported net revenue of $26.6 million, down from $46.5 million in the same period of 2024, with a gross profit margin contracting to 69% from 80% [6]. Group 3: Future Outlook - Zynex has issued a muted revenue guidance of $27 million for Q2 2025 and anticipates an earnings per share (EPS) loss of $0.20, withholding full-year financial guidance due to uncertainty with Tricare [8]. - The CEO of Zynex acknowledged the impact of the Tricare payment suspension on revenue and indicated that the company is initiating a restructuring effort [7].

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of misleading statements and improper business practices that have led to significant financial losses for investors during the specified class period [3][4][5]. Group 1: Allegations and Lawsuit Details - The class action lawsuit claims that Zynex shipped medical products in quantities exceeding patient needs, resulting in inflated revenue figures [3]. - The lawsuit highlights that Zynex's practices attracted scrutiny from insurers, including Tricare, which could lead to negative consequences such as exclusion from insurer networks and potential penalties from federal agencies [3]. - A report published by STAT accused Zynex of operating an "oversupplying scheme," sending excessive quantities of supplies to bill insurers unjustifiably, which contributed to a decline in Zynex's stock price by over 5% following its release [4]. Group 2: Financial Impact - On March 11, 2025, Zynex announced a revenue shortfall for Q4 and full year 2024, attributing it to slower payments from certain payers, which included a temporary suspension of payments from Tricare pending a review of previous claims [5]. - Following the announcement of the revenue shortfall, Zynex's stock price plummeted by more than 51% [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, closing at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].